| HOME >> BIOLOGY >> TECHNOLOGY |
activities 7,150,000 8,459,000
Cash flows from financing activities:
Exercise of stock options 266,000 439,000
Exercise of warrants -- 1,083,000
Repurchase of common stock (293,000) --
Payments on capital lease obligations
and note payable (18,000) (16,000)
Net cash (used in) provided by
financing activities (45,000) 1,506,000
Net increase (decrease) in cash and cash
equivalents (1,346,000) 2,203,000
Cash and cash equivalents at beginning
of year 5,730,000 3,527,000
Cash and cash equivalents at end of year $4,384,000 $5,730,000
Supplemental non-cash financing and
investing information
Equipment acquired by not
payable/capital lease -- $17,000
Transfer of inventories to equipment $157,000 $124,000
Transfer of equipment to inventories $42,000 $69,000
About ThermoGenesis Corp.
ThermoGenesis Corp. (http://www.thermogenesis.com) is a leader in
developing and manufacturing automated blood processing systems and
disposable products that enable the manufacture, preservation and delivery
of cell and tissue therapy products. These products include:
-- The BioArchive(R) System, an automated cryogenic device, is used by
cord blood stem cell banks in more than 25 countries for cryopreserving
and archiving cord blood stem cell units for transplant.
-- AXP(TM) AutoXpress Platform (AXP(TM)) is a proprietary family of
automated devices that includes the AXP and the Mar
'/>"/>
| SOURCE ThermoGenesis Corp. Copyright©2008 PR Newswire. All rights reserved |